Kobo Biotech Limited (KOBO) Fair Value & Analysis
Healthcare · IN · Market cap ₹116M
Strengths
Risks
Fair value as of: Aug 25, 2026
From 2 valuation models · updated yesterday
Share price −39.9% over the past month.
A solid business, but trading 62% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.
How to read this chart
60‑month range ₹1.90 – ₹10.85 · the ₹5.35 price screens above the ₹3.30 fair value. Dashed = 300-day average. As of Aug 25, 2026.
Analysis
Kobo Biotech Limited (KOBO) currently trades at ₹5.35, while our model-based Fair Value estimate is ₹3.30, implying the stock looks roughly 38.3% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at ₹760K. Net debt stands at ₹1.4B. Fundamentals as of Aug 25, 2026
The share trades about 35% below its 52-week high and 169% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at -38%, KOBO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: DCF Models (₹5.51) versus Growth DCF (₹5.07). Highest evidence: Growth DCF (80).
Notify me when KOBO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 78
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Kobo Biotech Limited manufactures active pharmaceutical ingredients based on fermentation technology in India. The company was formerly known as Avon Lifesciences Limited and changed its name to Kobo Biotech Limited in October 2020. Kobo Biotech Limited was incorporated in 1993 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kobo Biotech Limited reported revenue of ₹0 in FY2025 versus ₹0 in FY2021. Reported net income was −₹52.3M in FY2025.
KOBO screens 38% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 633 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.00 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $17.41 | $11.29 | -35% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $36.74 | $15.37 | -58% |
| Sandoz Group SDZ | CHF 72.64 | CHF 48.68 | -33% |
| Zoetis Inc ZTS | $73.54 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Kobo Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kobo Biotech Limited (KOBO) overvalued or undervalued?
What is the fair value of KOBO?
What is the quality score of KOBO?
What is the revenue of Kobo Biotech Limited (KOBO)?
What is the net profit margin of KOBO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kobo Biotech Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.